stoxline Quote Chart Rank Option Currency Glossary
  
Matinas BioPharma Holdings, Inc. (MTNB)
0.5708  -0.029 (-4.87%)    02-19 16:00
Open: 0.619
High: 0.619
Volume: 286,827
  
Pre. Close: 0.6
Low: 0.5467
Market Cap: 3(M)
Technical analysis
2025-02-19 4:42:07 PM
Short term     
Mid term     
Targets 6-month :  0.75 1-year :  0.84
Resists First :  0.64 Second :  0.72
Pivot price 0.59
Supports First :  0.53 Second :  0.44
MAs MA(5) :  0.59 MA(20) :  0.6
MA(100) :  1.28 MA(250) :  5.76
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  35 D(3) :  37.5
RSI RSI(14): 44.3
52-week High :  21.5 Low :  0.47
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ MTNB ] has closed above bottom band by 21.1%. Bollinger Bands are 92.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 60 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.62 - 0.62 0.62 - 0.63
Low: 0.54 - 0.54 0.54 - 0.55
Close: 0.57 - 0.57 0.57 - 0.58
Company Description

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 free fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Allergy and Infectious Diseases for the development of Gilead's antiviral remdesivir; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. The company was incorporated in 2013 and is based in Bedminster, New Jersey.

Headline News

Thu, 13 Feb 2025
Matinas Biopharma Announces Agreement For The Acquisition Of Preferred Stock And Appointment Of Dr. Robin L. Smith To The Board Of Directors - Marketscreener.com

Thu, 13 Feb 2025
Matinas BioPharma Announces Agreement for the Acquisition of Preferred Stock and Appointment of Dr. Robin L. Smith to the Board of Directors - GlobeNewswire

Thu, 13 Feb 2025
Biotech Deal Alert: Matinas BioPharma Lands Critical $3.3M Investment While Strengthening Leadership - StockTitan

Fri, 07 Feb 2025
Matinas BioPharma Appoints Evelyn D’An to Board of Directors as Audit Committee Chair - StockTitan

Fri, 24 Jan 2025
Activist Investor 111 Equity Takes 5.17% Stake in Matinas BioPharma, Seeks Value Creation - StockTitan

Fri, 24 Jan 2025
111 Equity Group Increases Stake In Matinas Biopharma Holdings - citybiz

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
AMEX
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 5 (M)
Shares Float 5 (M)
Held by Insiders 2.5 (%)
Held by Institutions 15.7 (%)
Shares Short 58 (K)
Shares Short P.Month 27 (K)
Stock Financials
EPS -5.5
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 3.8
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -50.9 %
Return on Equity (ttm) -97.6 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -4.66
Qtrly Earnings Growth 0 %
Operating Cash Flow -18 (M)
Levered Free Cash Flow -9 (M)
Stock Valuations
PE Ratio -0.11
PEG Ratio 0
Price to Book value 0.14
Price to Sales 0
Price to Cash Flow -0.17
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android